

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT								
NATURE OF CONVEYANCE:	ASSIGNMENT								
CONVEYING PARTY DATA									
<table border="1"> <thead> <tr> <th>Name</th> <th>Execution Date</th> </tr> </thead> <tbody> <tr> <td>Moise Azria</td> <td>09/15/2003</td> </tr> <tr> <td>Simon David Bateman</td> <td>08/28/2003</td> </tr> <tr> <td>Shoufeng Li</td> <td>09/08/2003</td> </tr> </tbody> </table>		Name	Execution Date	Moise Azria	09/15/2003	Simon David Bateman	08/28/2003	Shoufeng Li	09/08/2003
Name	Execution Date								
Moise Azria	09/15/2003								
Simon David Bateman	08/28/2003								
Shoufeng Li	09/08/2003								
RECEIVING PARTY DATA									
Name:	Novartis AG								
Street Address:	Lichtstrasse 35								
City:	Basel								
State/Country:	SWITZERLAND								
Postal Code:	4056								
PROPERTY NUMBERS Total: 1									
<table border="1"> <thead> <tr> <th>Property Type</th> <th>Number</th> </tr> </thead> <tbody> <tr> <td>Application Number:</td> <td>10565455</td> </tr> </tbody> </table>		Property Type	Number	Application Number:	10565455				
Property Type	Number								
Application Number:	10565455								
CORRESPONDENCE DATA									
Fax Number:	(973)781-8064								
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>									
Phone:	862-778-5806								
Email:	denise.cooper@novartis.com								
Correspondent Name:	David R Kurlandsky								
Address Line 1:	One Health Plaza								
Address Line 2:	Bldg. 101								
Address Line 4:	East Hanover, NEW JERSEY 07936								
ATTORNEY DOCKET NUMBER:	PAT033288-US-PCT								
NAME OF SUBMITTER:	Denise R. Cooper								

CH \$40.00 10565455

Total Attachments: 4
 source=33288_Assignment#page1.tif

501181773

**PATENT
 REEL: 024414 FRAME: 0392**

source=33288_Assignment#page2.tif
source=33288_Assignment#page3.tif
source=33288_Assignment#page4.tif

ASSIGNMENT

We,

Moise AZRIA

residing at

Bundesplatz 6
Basel 4054
Switzerland

Simon David BATEMAN

residing at

4 Farrington Lane
Randolph, New Jersey 07869

Shoufeng LI

residing at

2108 Ackman Court
Bridgewater, New Jersey 08807,

for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, do hereby sell and assign to **Novartis AG**, a company organized under the laws of the Swiss Confederation, having a place of business at Lichtstrasse 35, Basel, Switzerland 4056, its successors, assigns and legal representatives, all our right, title and interest, which includes the right to and full benefit of such priorities as may now or hereafter be granted to us by local laws or by treaty, including any international convention for the protection of industrial property, in and for the United States and its territories and possessions in and to the invention entitled:

USE OF CALCITONIN IN OSTEOARTHRITIS


invented by us and described in the application for United States Letters Patent

Application No. 60/489,400, filed July 23, 2003,

including (1) said provisional application for United States Letters Patent and subsequent non-provisional or international application(s) designating the United States which claim the benefit of said provisional application, and all continuations and divisions thereof (including further continuations and divisions such as, but not limited to, continuations of continuations and divisions of continuations), (2) all United States Letters Patent which may be issued and/or granted on all such applications, (3) all applications for reissues and extensions of and reexamination certificates for all such United States Letters Patent and (4) all reissues and extensions and reexamination certificates issued for all such United States Letters Patent, the said interest being the entire ownership of said invention and all of said applications, United States Letters Patent (including reissue Letters Patent), extensions and reexamination certificates to be held and enjoyed by the said Novartis AG and its successors and assigns to the full end of the terms to which said United States Letters Patent (including reissue Letters Patent), extensions and reexamination certificates may be granted and/or issued, as fully and

entirely as the same would have been held and enjoyed by us if this sale, assignment and transfer had not been made;

And we hereby agree to sign and/or execute any further documents and/or instruments which may be necessary, lawful and proper in and/or for the filing and/or prosecution of said applications for United States Letters Patent (including reissue Letters Patent), extensions and reexamination certificates and/or the granting and/or issuance thereof and/or to otherwise secure title to said invention and all of said applications, United States Letters Patent (including reissue Letters Patent), extensions and reexamination certificates in said assignee.

Signed this 15 day of September, 2003 by 
Moïse AZRIA

Signed this _____ day of _____, 2003 by _____
Simon David BATEMAN

Signed this _____ day of _____, 2003 by _____
Shoufeng LI

ASSIGNMENT

We,

Moise AZRIA	residing at	Bundesplatz 6 Basel 4054 Switzerland
Simon David BATEMAN	residing at	4 Farrington Lane Randolph, New Jersey 07869
Shoufeng LI	residing at	2108 Ackman Court Bridgewater, New Jersey 08807,

for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, do hereby sell and assign to **Novartis AG**, a company organized under the laws of the Swiss Confederation, having a place of business at Lichtstrasse 35, Basel, Switzerland 4056, its successors, assigns and legal representatives, all our right, title and interest, which includes the right to and full benefit of such priorities as may now or hereafter be granted to us by local laws or by treaty, including any international convention for the protection of industrial property, in and for the United States and its territories and possessions in and to the invention entitled:

USE OF CALCITONIN IN OSTEOARTHRITIS

invented by us and described in the application for United States Letters Patent

Application No. 60/489,400, filed July 23, 2003,

including (1) said provisional application for United States Letters Patent and subsequent non-provisional or international application(s) designating the United States which claim the benefit of said provisional application, and all continuations and divisions thereof (including further continuations and divisions such as, but not limited to, continuations of continuations and divisions of continuations), (2) all United States Letters Patent which may be issued and/or granted on all such applications, (3) all applications for reissues and extensions of and reexamination certificates for all such United States Letters Patent and (4) all reissues and extensions and reexamination certificates issued for all such United States Letters Patent, the said interest being the entire ownership of said invention and all of said applications, United States Letters Patent (including reissue Letters Patent), extensions and reexamination certificates to be held and enjoyed by the said Novartis AG and its successors and assigns to the full end of the terms to which said United States Letters Patent (including reissue Letters Patent), extensions and reexamination certificates may be granted and/or issued, as fully and

entirely as the same would have been held and enjoyed by us if this sale, assignment and transfer had not been made;

And we hereby agree to sign and/or execute any further documents and/or instruments which may be necessary, lawful and proper in and/or for the filing and/or prosecution of said applications for United States Letters Patent (including reissue Letters Patent), extensions and reexamination certificates and/or the granting and/or issuance thereof and/or to otherwise secure title to said invention and all of said applications, United States Letters Patent (including reissue Letters Patent), extensions and reexamination certificates in said assignee.

Signed this day of , 2003 by _____
Moise AZRIA

Signed this 28 day of August , 2003 by Simon David Bateman
Simon David BATEMAN

Signed this 8 day of September, 2003 by Shoufeng LI
Shoufeng LI